The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of the booming market for GLP-1s.
Related Posts
Trump getting Apple to produce iPhones in the U.S. is a ‘fairy tale,’ says Dan Ives
Still, the analyst maintained his outperform rating.
Berkshire Hathaway shares dip nearly 3% after shocking Buffett exit and an earnings decline
Investors are processing Warren Buffett’s surprise announcement to step down and envision a new path for the conglomerate after his legendary 60-year run.
Zelenskiy says Russia hit Ukraine’s power infrastructure, US should react
Moscow accused Kyiv on Wednesday of using drones to attack energy facilities in Russia’s Kursk and Bryansk regions, and in the occupied Crimean peninsula.